Neuphoria Therapeutics Sees Revenue Plummet by 92.5% in FY2026

Neuphoria Therapeutics Inc., a company that has been working on developing new treatments, reported disappointing financial results for its fiscal year 2026. The company's revenue declined by 92.5% to $1.17 million, compared to the previous year's $15.65 million. This sharp drop in revenue is attributed to the absence of a significant milestone payment from Merck, which was recognized in the prior year.

The loss before income taxes also widened to $13.59 million, up from $0.84 million in 2025. The company's core asset, BNC210, remained its focus area, but research and development activities were largely paused in October 2025 due to a strategic review and potential partnership or merger.

Neuphoria Therapeutics has ongoing collaborations with Merck and Carina, which provide non-dilutive milestone opportunities. The company also undertook operational restructuring in October 2025, reducing headcount, closing facilities, and lowering general and administrative expenses to preserve its cash runway into 2028.